BRPI1009783A2 - compostos para o tratamento de distúrbios metabólicos. - Google Patents
compostos para o tratamento de distúrbios metabólicos.Info
- Publication number
- BRPI1009783A2 BRPI1009783A2 BRPI1009783A BRPI1009783A BRPI1009783A2 BR PI1009783 A2 BRPI1009783 A2 BR PI1009783A2 BR PI1009783 A BRPI1009783 A BR PI1009783A BR PI1009783 A BRPI1009783 A BR PI1009783A BR PI1009783 A2 BRPI1009783 A2 BR PI1009783A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- metabolic disorders
- metabolic
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0904285.4A GB0904285D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
| PCT/GB2010/050441 WO2010103334A1 (en) | 2009-03-12 | 2010-03-12 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009783A2 true BRPI1009783A2 (pt) | 2016-03-08 |
Family
ID=40600947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009783A BRPI1009783A2 (pt) | 2009-03-12 | 2010-03-12 | compostos para o tratamento de distúrbios metabólicos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120059014A1 (pt) |
| EP (1) | EP2406251A1 (pt) |
| JP (1) | JP2012520283A (pt) |
| KR (1) | KR20110133045A (pt) |
| CN (1) | CN102395578A (pt) |
| AU (1) | AU2010222672A1 (pt) |
| BR (1) | BRPI1009783A2 (pt) |
| CA (1) | CA2754791A1 (pt) |
| CL (1) | CL2011002182A1 (pt) |
| EA (1) | EA201190207A1 (pt) |
| GB (1) | GB0904285D0 (pt) |
| IL (1) | IL215050A0 (pt) |
| MA (1) | MA33241B1 (pt) |
| MX (1) | MX2011009493A (pt) |
| PE (1) | PE20120218A1 (pt) |
| SG (1) | SG174363A1 (pt) |
| WO (1) | WO2010103334A1 (pt) |
| ZA (1) | ZA201107449B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| US8293729B2 (en) | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| GB201006167D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| NZ618795A (en) * | 2011-05-13 | 2015-07-31 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| GB2497351A (en) * | 2011-12-09 | 2013-06-12 | Prosidion Ltd | Compounds useful as GPR119 agonists |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2016131198A1 (en) * | 2015-02-18 | 2016-08-25 | Eli Lilly And Company | Pyrazole compounds |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| CA2344591A1 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Methods for improving the function of heterologous g protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| US8207147B2 (en) | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| KR20070091038A (ko) | 2004-12-24 | 2007-09-06 | 프로시디온 리미티드 | Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| JP2008545010A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇタンパク質共役受容体アゴニスト |
| JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| NZ571869A (en) | 2006-04-06 | 2011-11-25 | Prosidion Ltd | Heterocyclic GPCR agonists |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| JP5330260B2 (ja) * | 2006-12-06 | 2013-10-30 | スミスクライン ビーチャム コーポレーション | 二環式化合物ならびに抗糖尿病薬としての使用 |
| CL2008000018A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| EP2114933B1 (en) | 2007-01-04 | 2011-09-07 | Prosidion Ltd | Piperidine gpcr agonists |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| JP4455675B2 (ja) | 2007-10-18 | 2010-04-21 | 日鉱金属株式会社 | 金属被覆ポリイミド複合体及び同複合体の製造方法並びに電子回路基板の製造方法 |
| CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
| ATE557024T1 (de) | 2008-07-10 | 2012-05-15 | Prosidion Ltd | Piperidinverbindungen als gpcr-agonisten |
| GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| EA201170151A1 (ru) | 2008-07-10 | 2011-08-30 | Просидион Лимитед | Пиперидиниловые агонисты gpcr |
-
2009
- 2009-03-12 GB GBGB0904285.4A patent/GB0904285D0/en not_active Ceased
-
2010
- 2010-03-12 PE PE2011001638A patent/PE20120218A1/es not_active Application Discontinuation
- 2010-03-12 SG SG2011065802A patent/SG174363A1/en unknown
- 2010-03-12 BR BRPI1009783A patent/BRPI1009783A2/pt not_active Application Discontinuation
- 2010-03-12 EP EP10709053A patent/EP2406251A1/en not_active Withdrawn
- 2010-03-12 MX MX2011009493A patent/MX2011009493A/es unknown
- 2010-03-12 AU AU2010222672A patent/AU2010222672A1/en not_active Abandoned
- 2010-03-12 CA CA2754791A patent/CA2754791A1/en not_active Abandoned
- 2010-03-12 KR KR1020117024019A patent/KR20110133045A/ko not_active Withdrawn
- 2010-03-12 WO PCT/GB2010/050441 patent/WO2010103334A1/en not_active Ceased
- 2010-03-12 MA MA34245A patent/MA33241B1/fr unknown
- 2010-03-12 JP JP2011553533A patent/JP2012520283A/ja active Pending
- 2010-03-12 EA EA201190207A patent/EA201190207A1/ru unknown
- 2010-03-12 US US13/255,531 patent/US20120059014A1/en not_active Abandoned
- 2010-03-12 CN CN2010800171471A patent/CN102395578A/zh active Pending
-
2011
- 2011-09-05 CL CL2011002182A patent/CL2011002182A1/es unknown
- 2011-09-08 IL IL215050A patent/IL215050A0/en unknown
- 2011-10-11 ZA ZA2011/07449A patent/ZA201107449B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010222672A1 (en) | 2011-11-03 |
| MX2011009493A (es) | 2011-10-11 |
| JP2012520283A (ja) | 2012-09-06 |
| GB0904285D0 (en) | 2009-04-22 |
| CA2754791A1 (en) | 2010-09-16 |
| SG174363A1 (en) | 2011-10-28 |
| KR20110133045A (ko) | 2011-12-09 |
| US20120059014A1 (en) | 2012-03-08 |
| MA33241B1 (fr) | 2012-05-02 |
| WO2010103334A1 (en) | 2010-09-16 |
| ZA201107449B (en) | 2012-06-27 |
| CN102395578A (zh) | 2012-03-28 |
| CL2011002182A1 (es) | 2012-03-30 |
| PE20120218A1 (es) | 2012-03-19 |
| IL215050A0 (en) | 2011-11-30 |
| EA201190207A1 (ru) | 2012-04-30 |
| EP2406251A1 (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| LTC2137143I2 (lt) | Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui | |
| PL2504005T3 (pl) | Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby | |
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
| SMP200900085B (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative. | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| BRPI1013426A2 (pt) | organismos para produção de 1,3-butanodiol | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| GB0904287D0 (en) | Compounds for the treatment of metabolic disorders | |
| BRPI0813670A2 (pt) | Compostos para tratamento | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
| BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
| BRPI1013245A2 (pt) | "composto para o tratamento de distúrbios metabólicos" | |
| BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
| BRPI0906606A2 (pt) | Tratamento terapêutico para condições do pulmão. | |
| BR112013015048A2 (pt) | composição para o tratamento de distúrbios metabólicos | |
| BRPI0920728A2 (pt) | Composição estabilizada para tratamento de psoríase | |
| BR112012002267A2 (pt) | compostos para o tratamento de inflamação. | |
| GB201006167D0 (en) | Compounds for the treatment of metabolic disorders | |
| BRPI0922216A2 (pt) | tratamento para glomerulonefrite | |
| BRPI0923862A2 (pt) | Compostos sulfonamida para o tratamento de distúrbios respiratórios | |
| GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
| BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |